Evidence map›Paper›PMID 38868776›Full record

ArticleFrontiers in immunology2024

TIGIT

Natalie M Edner, Luke P Houghton, Elisavet Ntavli, Chloe Rees-Spear, Lina Petersone, Chunjing Wang, Astrid Fabri, Yassin Elfaki, Andrea Rueda Gonzalez, Rachel Brown and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Natalie M EdnerDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Luke P HoughtonDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Elisavet NtavliDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Chloe Rees-SpearDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Lina PetersoneDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Chunjing WangDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Astrid FabriDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Yassin ElfakiDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Andrea Rueda GonzalezDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Rachel BrownDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Kai KisandInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Pärt PetersonInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Laura E McCoyDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Lucy S K WalkerDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.

Funding

Medical Research Council MR/R008698/1
6 · The paper itself

Abstract

Circulating follicular helper T cells (cTfh) can show phenotypic alterations in disease settings, including in the context of tissue-damaging autoimmune or anti-viral responses. Using severe COVID-19 as a paradigm of immune dysregulation, we have explored how cTfh phenotype relates to the titre and quality of antibody responses. Severe disease was associated with higher titres of neutralising S1 IgG and evidence of increased T cell activation. ICOS, CD38 and HLA-DR expressing cTfh correlated with serum S1 IgG titres and neutralising strength, and interestingly expression of TIGIT by cTfh showed a negative correlation. TIGIT

Indexed as

Antibodies, ViralB-LymphocytesCOVID-19Receptors, ImmunologicSARS-CoV-2T Follicular Helper CellsAdultAgedAged, 80 and overAntibodies, NeutralizingFemaleHumansImmunoglobulin GLymphocyte ActivationMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GReceptors, ImmunologicTIGIT protein, humanantibody responseB cell helpCOVID-19follicular helper T cellsTIGIT

Identifiers

PMID38868776
PMCPMC11167088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.